scholarly journals Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia

2018 ◽  
Vol 8 (3) ◽  
pp. 153-158
Author(s):  
Samia Haque Tonu ◽  
Jesmine Fauzia Dewan ◽  
Fahmida Hasnat ◽  
Begum Rudaba Jahan
Keyword(s):  
Platelet Count ◽  
Serum Lipid ◽  
Thrombus Formation ◽  
Lipid Lowering ◽  
Atorvastatin Group ◽  
Beneficial Effects ◽  
Reductase Inhibitors ◽  
Significant Difference ◽  
Rosuvastatin Group ◽  
Coa Reductase

Background: Atorvastatin and rosuvastatin are two widely used HMG-CoA reductase inhibitors (statins). These are used as lipid-lowering drugs to reduce atherosclerosis-induced cardiovascular events. The beneficial effects of statins also involve some lipid-independent mechanisms which include modification of thrombus formation and degradation, alteration in inflammatory response, plaque stabilization and improvement of endothelial function.Objective: To compare antithrombogenic effect of atorvastatin and rosuvastatin in patients with hyperlipidemia.Materials and Methods: A prospective, open-labeled, interventional, randomized and single-center study was carried out in Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka from March, 2016 to August, 2017 on 52 hyperlipidemic patients. After randomization patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. Blood was collected at baseline and after intervention to measure platelet count, prothrombin time (PT) and serum lipid profile.Results: The baseline characteristics of patients treated with atorvastatin and rosuvastatin were almost identical. The platelet count in atorvastatin group was reduced after intervention (2.30%, p=0.463) which was not significant but in rosuvastatin group platelet count reduced significantly (12.33%, p=0.021) after intervention. There was no statistically significant difference (p=0.187) between the two statin treated groups. PT was increased significantly after intervention in both atorvastatin group (31.44%, p<0.001) and in rosuvastatin group (31.93%, p=0.003), which was statistically significant. No significant difference was observed between the two groups (p=0.573). Both atorvastatin and rosuvastatin significantly improved serum lipid profile.Conclusion: The present study reveals that rosuvastatin reduced thrombogenesis more effectively than atorvastatin in hyperlipidemic patients.J Enam Med Col 2018; 8(3): 153-158

scholarly journals A comparative study of atorvastatin and rosuvastatin on lipid lowering efficacy in hyperlipidemic patients

2018 ◽  
Vol 11 (1) ◽  
pp. 17
Author(s):  
Samia Haque Tonu ◽  
Zesmin Fauzia Dewan ◽  
Nargis Akhter ◽  
Sajal Krishna Banerjee
Keyword(s):  
Lipid Profile ◽  
Serum Triglyceride ◽  
Lipid Lowering ◽  
Serum Triglyceride Level ◽  
Intergroup Difference ◽  
Atorvastatin Group ◽  
Significant Difference ◽  
Rosuvastatin Group ◽  
Significant Change ◽  
Lipid Lowering Effect

<p class="Abstract">The aim of the present study was to compare the lipid lowering effect of atorvastatin and rosuvastatin in patients (n=52) with hyperlipidemia. Patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. The blood was collected at baseline and after intervention to measure serum lipid profile. The level of serum total cholesterol in both atorvastatin and rosuvastatin groups was significantly reduced after intervention (p&lt;0.00001 and p&lt;0.00001 respectively) but no statistically significant difference (p=0.503) was observed between the two statin-treated groups. The reduction of serum triglyceride level was also significant (p=0.046 in atorvastatin group and p=0.0006 in rosuvastatin group). No significant difference was observed between the two groups (p=0.312). The serum LDL-C level was reduced significantly in both atorvastatin group (p&lt;0.00001) and rosuvastatin group (p&lt;0.00001). Again no statistically significant difference (p= 0.749) was observed between the two groups. No significant change was observed in the serum HDL level. Intergroup difference was not significant (p= 0.721). The present study indicates that, both atorvastatin and rosuvastatin improve the lipid profile but no significant change was observed between the two groups.</p>

Translating the effects of statins: From redox regulation to suppression of vascular wall inflammation

2012 ◽  
Vol 108 (11) ◽  
pp. 840-848 ◽  
Author(s):  
Alexios Antonopoulos ◽  
Marios Margaritis ◽  
Cheerag Shirodaria ◽  
Charalambos Antoniades
Keyword(s):  
Nitric Oxide ◽  
Redox Regulation ◽  
Mevalonate Pathway ◽  
Vascular Wall ◽  
Statin Treatment ◽  
Lipid Lowering ◽  
Redox Signalling ◽  
Beneficial Effects ◽  
Reductase Inhibitors ◽  
Coa Reductase

SummaryVascular oxidative stress is a key feature of atherogenesis, and targeting vascular redox signalling is a rational therapeutic goal in vascular disease pathogenesis. 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors or statins are potent lipid-lowering drugs that improve cardiovascular outcomes. It is now widely accepted that cardiovascular disease prevention by statins is dependent not only on their lipid lowering effects, but also on their beneficial effects on vascular redox signalling. Cell culture and animal models have provided important findings on the effects of statins on vascular redox and nitric oxide bioavailability. Recent evidence from studies on human vessels has further enhanced our understanding of the “pleiotropic” effects of statins on vascular wall. Reversal of endothelial dysfunction in human vessels by statins is dependent on the mevalonate pathway and Rac1 inhibition. These critical steps are responsible for reducing NADPH-oxidase activity and improving tetrahydrobiopterin bioavailability and nitric oxide synthase (NOS) coupling in human vessels. However, mevalonate pathway inhibition has been also held responsible for some of the side effects observed after statin treatment. In this review we summarise the existing knowledge on the effects of statins on vascular biology by discussing key findings from basic science as well as recent evidence from translational studies in humans. Finally, we discuss emerging aspects of statin pleiotropy, such as their effects on adipose tissue biology and adipokine synthesis that may light additional mechanistic links between statin treatment and improvement of clinical outcome in primary and secondary prevention.

Treating Dyslipidemia for the Primary and Secondary Prevention of Stroke

2017 ◽  
Vol 37 (03) ◽  
pp. 286-293
Author(s):  
Fotios Barkas ◽  
Haralampos Milionis
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Stroke Risk ◽  
Therapeutic Interventions ◽  
Lipid Lowering ◽  
Prevention Measures ◽  
Primary And Secondary Prevention ◽  
Beneficial Effects ◽  
Reductase Inhibitors ◽  
Coa Reductase

AbstractStroke is associated with a heavy burden of mortality and disability, underscoring the importance of effective primary and secondary prevention measures. Dyslipidemia as a risk factor for ischemic stroke has long been disputed. Nevertheless, accumulating epidemiological evidence supports a role of lipid abnormalities in increasing ischemic stroke risk and representing a potential target for therapeutic interventions. 3-hydroxy-3-methyl-glutaryl- (HMG-) CoA reductase inhibitors (i.e., statins) are currently the mainstay of therapy for the management of hypercholesterolemia in patients with cardiovascular disease and stroke. Although their beneficial effects on stroke risk have been attributed chiefly to their lipid-lowering capacity, they also have pleiotropic effects. Other lipid lowering modalities have been shown to reduce the risk of ischemic stroke in individuals at high cardiovascular risk, but data regarding their use in secondary stroke prevention are lacking.

Statins and Inflammation in Cardiovascular Disease

2018 ◽  
Vol 23 (46) ◽  
pp. 7027-7039 ◽  
Author(s):  
Georgia Vogiatzi ◽  
Evangelos Oikonomou ◽  
Gerasimos Siasos ◽  
Sotiris Tsalamandris ◽  
Alexandros Briasoulis ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Lipid Lowering ◽  
Hmg Coa Reductase ◽  
Ample Evidence ◽  
Reductase Inhibitors ◽  
Immune System Activation ◽  
Hmg Coa Reductase Inhibitors ◽  
Anti Inflammatory ◽  
Artery Disease ◽  
Coa Reductase

Background: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The beneficial effects of HMG-CoA reductase inhibitors or statins are mainly attributed to their ability to inhibit hepatic cholesterol biosynthesis. Beyond their lipid lowering activity, ample evidence exists in support of their potent anti-inflammatory properties which initiate from the inhibition of GTPase isoprenylation, activating a cataract of secondary pathways and extend to the inhibition and blocking of immune cell activation and interaction. </P><P> Objective: To summarize the anti-inflammatory mechanisms of statins in clinical and experimental settings in cardiovascular disease. </P><P> Methods: A systematic search of PubMed and the Cochrane Database was conducted in order to identify the majority of trials, studies, current guidelines and novel articles related to the subject. </P><P> Results: In vitro, statins have immuno-modulatory and anti-inflammatory effects, and they can exert antiatherosclerotic effects independently of their hypolipidemic actions. In addition, positive results have emerged from mechanistic and experimental studies on the active role of HMG-CoA reductase inhibitors in HF. By extrapolating those data in clinical setting, we further understand how HMG-CoA reductase inhibitors can beneficially affect not only systolic but also diastolic HF. </P><P> Conclusion: In this review article, we present the basic pathophysiologic data supporting the anti-inflammatory actions of statins in clinical and experimental settings and we link these mechanisms with confirmatory clinical data on the potent non lipid lowering effects of HMG-CoA reductase inhibitors.

scholarly journals ANALYSIS OF THE CURRENT STATE AND THE DYNAMICS OF LIPID-LOWERING DRUGS IN THE PHARMACEUTICAL MARKET OF UKRAINE

2018 ◽  
Vol 11 (6) ◽  
pp. 358
Author(s):  
Kotvitska Alla A ◽  
Cherkashyna Alina V ◽  
Volkova Alina V ◽  
Kubarieva Inna V
Keyword(s):  
Pharmaceutical Market ◽  
Lipid Lowering ◽  
Market Segment ◽  
Primary Methods ◽  
Lipid Lowering Drugs ◽  
Reductase Inhibitors ◽  
Current State ◽  
Market Niche ◽  
Rosuvastatin Group ◽  
Physical Availability

Objective: The purpose of this study was to analyze the assortment, availability, consumption status, and dynamics of lipid-lowering drugs in the pharmaceutical market in Ukraine.Methods: Among the primary methods of research were applied the following: System and content analysis, marketing, logical and mathematical analysis, graphical mode, and also a way of detailed and abstract simulation and synthesis.Results: The ratio of imported and domestic lipid-lowering drugs in Ukrainian pharmaceutical market was analyzed (imported lipid-lowering medicines account for 82% of the total number of this group in Ukrainian market, the share of local medications is 18%, respectively). The structural review and analysis of market characteristics of 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors group of medicines (sales, accessibility for people, and competitiveness) were conducted, and the most promising market segment for producers and distributors was identified. The most promising sector is rosuvastatin, which is characterized by an average sales volume with a tendency to increase and a high increasing profit.Conclusion: Data on dynamics of the development of lipid-lowering drugs segment in the pharmaceutical market of Ukraine are systematized, which enables potential manufacturers to identify their market niche. As a result of the study, heavy dependency on imported lipid-lowering drugs in the pharmaceutical market of Ukraine was established, which determines low economic accessibility (especially in case of increasing in exchange rates) and physical availability (dependence on the regularity of shipments to Ukraine) for consumers. The most competitive medicines of atorvastatin and rosuvastatin group were determined, it was established that sales leader was pharmaceutical company KRKA dd, Novo Mesto (Slovenia) with generics Atoris and Roxer.

Atorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias

1998 ◽  
Vol 32 (10) ◽  
pp. 1030-1043 ◽  
Author(s):  
Helen S Yee ◽  
Nancy T Fong
Keyword(s):  
Clinical Trials ◽  
Clinical Studies ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Hmg Coa Reductase ◽  
Apo B ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
The Impact

OBJECTIVE: To review the efficacy and safety of atorvastatin in the treatment of dyslipidemias. DATA SOURCES: A MEDLINE search (January 1960–April 1998), Current Contents search, additional references listed in articles, and unpublished data obtained from the manufacturer were used to identify data from scientific literature. Studies evaluating atorvastatin (i.e., abstracts, clinical trials, proceedings, data on file with the manufacturer) were considered for inclusion. STUDY SELECTION: English-language literature was reviewed to evaluate the pharmacology, pharmacokinetics, therapeutic use, and adverse effects of atorvastatin. Additional relevant citations were used in the introductory material and discussion. DATA EXTRACTION: Open and controlled animal and human clinical studies published in the English-language literature were reviewed and evaluated. Clinical trials selected for inclusion were limited to those in human subjects and included data from animals if human data were not available. DATA SYNTHESIS: Atorvastatin is a recent hydroxymethylglutarylcoenzyme A (HMG-CoA) reductase inhibitor for the treatment of primary hypercholesterolemia, mixed dyslipidemias, and homozygous familial hypercholesterolemia. In patients who have not met the low-density lipoprotein cholesterol (LDL-C) goal as recommended by the National Cholesterol Education Program Adult Treatment Panel II guidelines, atorvastatin 10–80 mg/d may be used as monotherapy or as an adjunct to other lipid-lowering agents and dietary modifications. In placebo-controlled clinical trials, atorvastatin 10–80 mg/d lowered LDL-C by 35–61% and triglyceride (TG) concentrations by 14–45%. In comparative trials, atorvastatin 10–80 mg/d showed a greater reduction of serum total cholesterol (TC), LDL-C, TG concentrations, and apolipoprotein B-100 (apo B) compared with pravastatin, simvastatin, or lovastatin. In comparison, currently available HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin) lower LDL-C concentrations by approximately 20–40% and TG concentrations by approximately 10–30%. In pooled placebo-controlled clinical trials of up to a duration of 52 weeks, atorvastatin in dosages up to 80 mg/d appeared to be well tolerated. The most common adverse effect of atorvastatin was gastrointestinal upset. The incidence of elevated serum hepatic transaminases may be greater at higher dosages of atorvastatin. The risk of myopathy and/or rhabdomyolysis is increased when an HMG-CoA reductase inhibitor is taken concomitantly with cyclosporine, gemfibrozil, niacin, erythromycin, or azole antifungals. CONCLUSIONS: Atorvastatin appears to reduce TC, LDL-C, TG concentrations, and apo B to a greater extent than do currently available HMG-CoA reductase inhibitors. Atorvastatin may be preferred in patients requiring greater than a 30% reduction in LDL-C or in patients with both elevated LDL-C and TG concentrations, which may obviate the need for combination lipid-lowering therapy. Adverse effects of atorvastatin appear to be similar to those of other HMG-CoA reductase inhibitors and should be routinely monitored. Long-term safety data (>1 y) on atorvastatin compared with other HMG-CoA reductase inhibitors are still needed. Cost-effectiveness studies comparing atorvastatin with other HMG-CoA reductase inhibitors remain a subject for further investigation. Published clinical studies evaluating the impact of atorvastatin on cardiovascular morbidity and mortality are still needed. Additionally, clinical studies evaluating the impact of lipid-lowering therapy in a larger number of women, the elderly (>70 y), and patients with diabetes for treatment of primary and secondary prevention of coronary heart disease are needed.

scholarly journals Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer

2021 ◽  
Author(s):  
Yoichi Morofuji ◽  
Shinsuke Nakagawa ◽  
Kenta Ujifuku ◽  
Takashi Fujimoto ◽  
Kaishi Otsuka ◽  
...  
Keyword(s):  
Cell Types ◽  
Pharmacological Action ◽  
Cerebrovascular Diseases ◽  
Lipid Lowering ◽  
Neuroprotective Effects ◽  
First Line Therapy ◽  
Reductase Inhibitors ◽  
Growth Inhibitory ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are administered as first-line therapy for hypercholesterolemia, both as primary and secondary prevention. Besides the lipid-lowering effect, statins have been suggested to inhibit the development of cardiovascular disease through anti-inflammatory, antioxidant, vascular endothelial function-improving, plaque-stabilizing, and platelet aggregation-inhibiting effects. The preventive effect of statins on atherothrombotic stroke has been well established, but statins can influence other cerebrovascular diseases. This suggests that statins have many neuroprotective effects in addition to lowering cholesterol. Furthermore, research suggests that statins cause pro-apoptotic, growth-inhibitory, and pro-differentiation effects in various malignancies. Preclinical and clinical evidence suggests that statins inhibit tumor growth and induce apoptosis in specific cancer cell types. The pleiotropic effects of statins on cardiovascular and cerebrovascular diseases have been well established; however, the effects of statins on cancer patients have not been fully elucidated and are still controversial. This review discusses the recent evidence on the effects of statins on cardiovascular and cerebrovascular diseases and cancer. Additionally, this study describes the pharmacological action of statins, focusing on the aspect of &lsquo;beyond lipid-lowering.&rsquo;

scholarly journals Antioxidatant Effect of Atorvastatin and Rosuvastatin in Hyperlipidemic Patients: A Randomized Controlled Trial

2019 ◽  
Vol 14 (1) ◽  
pp. 54-58
Author(s):  
Samia Haque Tonu ◽  
Jasmine Fauzia Dewan ◽  
Nargis Akhter ◽  
Md Enamul Haque ◽  
Md Abdul Wahab
Keyword(s):  
Oxidative Stress ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Controlled Trial ◽  
Armed Forces ◽  
Cardiovascular Complications ◽  
Serum Lipid Profile ◽  
Beneficial Effects ◽  
Significant Difference ◽  
Oxidative Stress Status

Introduction: Hyperlipidemia is a major risk for the development of atherosclerosis leading to cardiovascular complications. Atorvastatin and rosuvastatin are two widely used important members of the HMG-CoA reductase inhibitor (statins). The beneficial effects of statins on clinical events also involve lipid-independent mechanisms which include improvement of oxidative stress status. Objective: To compare the antioxidative effect of atorvastatin and rosuvastatin in patients with hyperlipidemia. Materials and Methods: A prospective randomized single-center analytic study was carried out in Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka from March 2016 to August 2017 on 52 hyperlipidemic patients. After randomization patients were assigned to atorvastatin 10 mg or rosuvastatin 5 mg daily for 8 weeks. Blood was collected at baseline and after the intervention to measure plasma malondialdehyde (MDA), erythrocyte reduced glutathione (GSH) (as biomarkers of oxidative stress) and serum lipid profile. Results: The baseline characteristics of patients treated with atorvastatin and rosuvastatin were almost identical. The level of plasma MDA in atorvastatin (1.35 ± 0.94 to 0.97± 0.64) and rosuvastatin (1.56±0.69 to 0.98±0.38) group was significantly reduced after intervention (28.15%, p<0.05 and 37.18%, p<0.001 respectively) but no statistically significant difference (p>0.05) was observed between the two statin-treated groups. Erythrocyte GSH level was increased after intervention in both atorvastatin (2.43±2.90 to 4.14 ± 4.87) group (70.37%, p<0.01) and rosuvastatin (2.76±3.80 to 8.36±12.93)  group (202.90%, p<0.01), which was statistically significant. No significant difference was observed between the two groups (p>0.05). Both atorvastatin and rosuvastatin significantly improved serum lipid profile. Conclusion: Both atorvastatin and rosuvastatin significantly improved oxidative stress status in hyperlipidemic patients but no significant change was observed between the two statin-treated groups. Journal of Armed Forces Medical College Bangladesh Vol.14(1) 2018: 54-58

Sign in / Sign up

Export Citation Format

Share Document